Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.
Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.
复制标题
DOI：
10.1155/2015/132326
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Carr A
中科院分区：
文献类型：
--
作者：
Blanco R;Domínguez E;Morales O;Blanco D;Martínez D;Rengifo CE;Viada C;Cedeño M;Rengifo E;Carr A
N-羟氨酰 GM3 神经节苷脂 (NeuGcGM3) 表达在非小细胞肺癌 (NSCLC) 中的预后作用仍存在争议。在这项研究中，使用更多的 NSCLC 病例和 14F7 Mab（针对 NeuGcGM3 的高度特异性 IgG1）重新评估了 NeuGcGM3 表达。应用结合 14F7 阳性细胞百分比和反应强度的免疫组织化学评分来重新评估 NeuGcGM3 表达、一些临床病理特征和 NSCLC 患者总生存 (OS) 之间的关系。还评估了 NeuGcGM3 与表皮生长因子受体 (EGFR) 和/或其配体表皮生长因子 (EGF) 的双重和三重表达。 NeuGcGM3 表达与 S 期分数 (p = 0.006) 和增殖指数 (p = 0.000) 相关。此外，在单变量（p = 0.020）和多变量（p = 0.010）分析中，NeuGcGM3 表达与患者较差的 OS 相关。此外，肿瘤对 NeuGcGM3、EGFR 和/或 EGF 的双重和/或三重阳性使我们能够识别具有更具侵袭性生物学行为的 NSCLC 表型。我们的结果与 NSCLC 患者中 NeuGcGM3 表达的负面预后意义一致。然而，建议确定非小细胞肺癌中 NeuGcGM3 表达的技术标准化以及通用评分系统的实施。
The prognostic role of N-glycolyl GM3 ganglioside (NeuGcGM3) expression in non-small cell lung carcinoma (NSCLC) still remains controversial. In this study, the NeuGcGM3 expression was reevaluated using an increased number of NSCLC cases and the 14F7 Mab (a highly specific IgG1 raised against NeuGcGM3). An immunohistochemical score integrating the percentage of 14F7-positive cells and the intensity of reaction was applied to reassess the relationship between NeuGcGM3 expression, some clinicopathological features, and the overall survival (OS) of NSCLC patients. The double and the triple expression of NeuGcGM3 with the epidermal growth factor receptor (EGFR) and/or its ligand, the epidermal growth factor (EGF), were also evaluated. NeuGcGM3 expression correlates with both S-Phase fraction (p = 0.006) and proliferation index (p = 0.000). Additionally, NeuGcGM3 expression was associated with a poor OS of patients in both univariate (p = 0.020) and multivariate (p = 0.010) analysis. Moreover, the double and/or the triple positivity of tumors to NeuGcGM3, EGFR, and/or EGF permitted us to identify phenotypes of NSCLC with a more aggressive biological behavior. Our results are in agreement with the negative prognostic significance of NeuGcGM3 expression in NSCLC patients. However, standardization of techniques to determine the expression of NeuGcGM3 in NSCLC as well as the implementation of a universal scoring system is recommended.